🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors

Recruitingn/aAges any - anyAllEuropean Institute of Oncology
NCT07429851 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pulmonary NETs are managed using extrapolated algorithms from duodeno-pancreatic NETs, underlining a significant unmet clinical need. This is likely due to the rarity, uncertain pathological and molecular classification, and heterogeneous clinical course of well differentiated high grade pulmonary NETs. In this study a retrospective data-base of pulmonary, thymic and duodeno-pancreatic NETs with Ki-67 \> 20% will be created in order to analyze diagnostic and therapeutic pathways, clinical outcomes

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist. * Primary tumor site:thyme, lung and duodenum-pancreas NETs. * Advanced stage of tumor disease and Any number of lines of therapy * Sufficient available clinical data on diagnosis, treatments, outcomes. Exclusion Criteria: * Poorly differentiated neuroendocrine carcinomas (NECs), GEP NET G1/G2, pulmonary carcinoid with Ki-67 \< 20%. * Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) * Inadequate or unavailable tumor tissue for molecular analysis. * Incomplete clinical records or follow-up. * Other primary sites, except lung or pancreas.
💊

What it tests

  • Not listed
📍

Where

1 site
European Institute of Oncology
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy